… This decision was based on the poor reporting quality of data in letters and conference
abstracts encountered in a previous version of our review (Lexchin 2003). A comment to the …

Objective To investigate whether funding of drug studies by the pharmaceutical industry is
associated with outcomes that are favourable to the funder and whether the methods of trials …

Background Pharmaceutical companies spent $57.5 billion on pharmaceutical promotion in
the United States in 2004. The industry claims that promotion provides scientific and …

Kefauver, Chairman of the United States Senate’s Anti-Trust and Monopoly Subcommittee,
put together the first extensive indictment against the business workings of the …

… In 2007, Joel Lexchin was retained by a law firm representing Apotex to provide expert
testimony about the effects of promotion on the sales of medications. From 2007 to 2008 he was …

OBJECTIVE: To determine the effect of three types of interaction between physicians and
the pharmaceutical industry--company-funded clinical trials, company-sponsored continuing …

… Kravitz, Bassett and Lexchin contributed to data interpretation, review of drafts of the manuscript
and, to a lesser extent, study plan, questionnaire and data collection. Drs. Kazanjian and …

… The real innovation crisis, say Donald Light and Joel Lexchin, stems from current
incentives that reward companies for developing large numbers of new drugs with few clinical …

Only the United States and New Zealand allow advertising of prescription drugs directed at
patients. US spending on such advertising grew rapidly during the 1990s, reaching $2.47 bn (…

Background Pharmaceutical costs are the fastest-growing health-care expense in most
developed countries. Higher drug costs have been shown to negatively impact patient outcomes. …